Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Anemia × LY2787106 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Interventions

Epoetin Alfa 51 Darbepoetin alfa 35 epoetin beta 14 ferric carboxymaltose 11 Cyclophosphamide 5 luspatercept 4 fludarabine phosphate 4 fludarabine 4 Erythropoietin 4 Cyclosporine 4 Cisplatin 4 Busulfan 4 Blood Transfusion 4 ACE-011 4 peginesatide 3 hematide 3 ferrous sulfate 3 ferric gluconate 3 Radiotherapy 3 Lenalidomide 3 Iron-Dextran Complex 3 Filgrastim 3 Erythrocyte Transfusion 3 Biopsy 3 Antilymphocyte Serum 3 thymoglobulin 2 ruxolitinib 2 iron isomaltoside 1000 2 ferrous fumarate 2 continuous erythropoietin receptor activator 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01340976 2018-10-03

A Phase 1 Study of LY2787106 in Cancer and Anemia

Eli Lilly and Company

Phase 1 Completed

33 enrolled 18 charts

Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡